Robert Howard
University of Nottingham
2 Papers
Robert Howard is an academic researcher from University of Nottingham. The author has contributed to research in topics: Medicine & Meta-analysis. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.
Charles R. Beck,Bruce C. McKenzie,Ahmed Hashim,Rebecca Harris,Arina Zanuzdana,Gabriel Agboado,Elizabeth Orton,Laura Béchard-Evans,Gemma S Morgan,Charlotte Stevenson,Rachel Weston,Mitsuru Mukaigawara,Joanne E. Enstone,Glenda Augustine,Mobasher Butt,Sophie Kim,Richard Puleston,Girija Dabke,Robert Howard,Julie O'Boyle,Mary O'Brien,Lauren Ahyow,Helene Denness,Siobhan Farmer,Jose Figureroa,Paul Fisher,Felix Greaves,Munib Haroon,Sophie Haroon,Caroline Hird,Rachel Isba,David A. Ishola,Marko Kerac,Vivienne Parish,Jonathan Roberts,Julia Rosser,Sarah Theaker,Dean Wallace,Neil Wigglesworth,Liz Lingard,Yana Vinogradova,Hiroshi Horiuchi,Javier Peñalver,Jonathan S. Nguyen-Van-Tam +43 more
TL;DR: Infection prevention and control strategies should recommend vaccinating immunocompromised patients, and the evidence reviewed is generally weak, although the directions of effects are consistent.
Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis
Charles R. Beck,Bruce C. McKenzie,Ahmed Hashim,Rebecca Harris,Arina Zanuzdana,Gabriel Agboado,Elizabeth Orton,Laura Béchard-Evans,Gemma S Morgan,Charlotte Stevenson,Rachel Weston,Mitsuru Mukaigawara,Joanne E. Enstone,Glenda Augustine,Mobasher Butt,Sophie Kim,Richard Puleston,Girija Dabke,Robert Howard,Julie O'Boyle,Mary O'Brien,Lauren Ahyow,Helene Denness,Siobhan Farmer,Jose Figureroa,Paul Fisher,Felix Greaves,Munib Haroon,Sophie Haroon,Caroline Hird,Rachel Isba,David A. Ishola,Marko Kerac,Vivienne Parish,Jonathan Roberts,Julia Rosser,Sarah Theaker,Dean Wallace,Neil Wigglesworth,Liz Lingard,Yana Vinogradova,Hiroshi Horiuchi,Javier Peñalver,Jonathan S. Nguyen-Van-Tam +43 more
TL;DR: The data show that whilst the serological response following vaccination of immunocompromised patients is less vigorous than in healthy controls, clinical protection is still meaningful, with only mild variation in adverse events between aetiological groups.